Reprogramming Cancer into Antigen-Presenting Cells as a Novel Immunotherapy

Area of Science:

• Immunology
• Oncology
• Cell Biology

Background:

• Therapeutic cancer vaccination aims to activate tumor-reactive T cells for cancer eradication.
• Current cancer vaccination benefits are limited, necessitating novel strategies.
• Tumor-reprogrammed antigen-presenting cells (TR-APCs) offer a promising new avenue.

Purpose of the Study:

• To present a novel cancer vaccination approach using myeloid-lineage reprogramming of cancer cells into TR-APCs.
• To demonstrate the efficacy of TR-APCs in activating anti-cancer immunity.
• To explore the broad applicability of this approach in various cancer types and clinical settings.

Main Methods:

• Utilized syngeneic murine leukemia models to investigate TR-APC induction.
• Assessed TR-APC phenotype, antigen processing and presentation capabilities.
• Evaluated T-cell stimulation, in vivo immune response, and tumor eradication.
• Generated TR-APCs from primary clinical specimens for autologous T-cell stimulation.

Main Results:

• TR-APCs acquired myeloid characteristics and effectively processed/presented endogenous tumor-associated antigens (TAAs).
• TR-APCs potently stimulated TAA-specific CD4+ and CD8+ T cells.
• In vivo TR-APC induction led to T-cell expansion, immune memory, and leukemia eradication.
• Hematologic cancers, sarcomas, and carcinomas were amenable to reprogramming; clinical specimens yielded functional TR-APCs.

Conclusions:

• TR-APCs represent a viable cancer vaccination strategy by converting cancer cells into potent antigen-presenting cells.
• This reprogramming-based immunotherapy demonstrates broad applicability across diverse malignancies.
• TR-APCs hold significant potential for clinical immuno-oncology applications.